De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?

Roberto Iacovelli, Chiara Ciccarese, Claudia Mosillo, Giampaolo Tortora

Research output: Contribution to journalComment/debatepeer-review

Abstract

Patients who receive a diagnosis of metastatic castration-sensitive prostate cancer (CSPC) have different phenotypes of disease. Some of them have de novo CSPC, but others receive a late diagnosis, and still others underwent prostatectomy several years before the diagnosis of metastases. We analyze the presence of these differences in recent clinical trials in CSPC and assess the possible impact on their results.

Original languageEnglish
Pages (from-to)482-484
Number of pages3
JournalClinical Genitourinary Cancer
Volume16
Issue number6
DOIs
Publication statusPublished - Dec 1 2018

Keywords

  • Abiraterone
  • CSPC
  • Docetaxel
  • HSPC
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint

Dive into the research topics of 'De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?'. Together they form a unique fingerprint.

Cite this